866-997-4948(US-Canada Toll Free)

Investigation Report on China Latanoprost Market, 2010-2019

Published By :

China Research and Intelligence Co., Ltd. (CRI)

Published Date : Jul 2015

Category :

Therapeutic Area

No. of Pages : 30 Pages


Glaucoma is an irreversible eye disorder which can lead to blindness. According to the statistics published by WHO in 2005, glaucoma is the second-leading cause of blindness after cataract. The number of glaucoma patients around the world is 70 million and will reach 80 million by 2020. And 50% of blindness cases in the world are caused by glaucoma. According to epidemiological studies of eye disease, by Feb. 2015, 2.3% of people aged above 40 suffer from glaucoma, among which about 30% may become blind. And it is predicted that by 2020, there will be about 21 million glaucoma patients in China. Developed by Pharmacia & Upjohn in 1995, latanoprost is a selective prostaglandin receptor agonist which effectively reduces intraocular pressure. As the first pressure-lowering prostaglandin approved by FDA, latanoprost (under the trade name of Xalatan) entered China in 1999. In 2004, latanoprost eye drop developed by Lunan Better Pharmaceutical Co., Ltd was approved to be marketed, followed by products of Merro Pharmaceutical Co., Ltd, Hengrui Pharmaceutical and China Resources Zizhu Pharmaceutical Co., Ltd. Latanoprost has already become the first-line drug for the treatment of glaucoma. 

Latanoprost develops fast after entering China, sales value rising from CNY 25.27 million in 2013 to CNY 26.40 million in 2014 with a year-on-year growth of 4.47% and CAGR during the period of 2010-2014 reaching 24.02%. With ageing population, the incidence of glaucoma continues to increase. Unlike cataract which can be treated with surgery, glaucoma provides a large market for conservative and postoperative medication. Therefore, latanoprost enjoys a vast demand in China. Pfizer Manufacturing Belgium NV, Pharmacia & Upjohn (Belgium), Lunan Better Pharmaceutical Co., Ltd, China Resources Zizhu Pharmaceutical Co., Ltd and Pharmacia & Upjohn (Sweden) occupy the majority of the market share, among which Pfizer Manufacturing Belgium NV had the largest market share of about 43.1% for sales value in 2014. However, its market share was even larger i.e. 44.3% in 2013. Meanwhile, the market share of Pharmacia & Upjohn also decreased from 30.8% in 2013 to 29.5% in 2014. On the contrary, local manufacturers like Lunan Better Pharmaceutical Co., Ltd and China Resources Zizhu Pharmaceutical Co., Ltd both reported an increased market share (a 1.5% increase from 13.7% to 15.2% achieved by Lunan Better) in 2014 and will gain a larger share as biological technology develops further and they come to know more about domestic drugs. 

Readers can get at least the following information from this report:
  • market size of latanoprost in China
  • major manufacturers of latanoprost in Chinese market
  • retail price of latanoprost in China
  • market outlook of latanoprost in China
The author suggests the following groups of people purchase this report:
  • manufacturers of ophthalmic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the medicine market, please contact CRI for customized survey service

1 Related Concepts of Latanoprost
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Latanoprost in China
2.1 Patent Status and Approval Information of Latanoprost in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Latanoprost in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Latanoprost in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Latanoprost in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Latanoprost in Chinese Hospitals in 2014
6.1 Pfizer Manufacturing Belgium NV (Trade Name: Xalatan)
6.2 Pharmacia & Upjohn (Belgium) (Trade Name: Xalatan)
6.3 Lunan Better Pharmaceutical Co., Ltd (Trade Name: Telijie)

7 Major Manufacturers of Latanoprost in Chinese Market, 2010-2014
7.1 Pfizer Manufacturing Belgium NV
7.2 Pharmacia & Upjohn (Belgium)
7.3 Lunan Better Pharmaceutical Co., Ltd
7.4 China Resources Zizhu Pharmaceutical Co., Ltd

8 Market Outlook of Latanoprost in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

List of Chart


Chart Patent Status of Latanoprost in China
Chart Approval Information of Latanoprost in China
Chart Sales Status of Latanoprost in China
Chart Sales Value of Latanoprost in China, 2010-2014
Chart Sales Value of Latanoprost in Some Regions in China, 2010-2014
Chart Sales Volume of Latanoprost in China, 2010-2014
Chart Sales Volume of Latanoprost in Some Regions in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Latanoprost for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Latanoprost Made by Pfizer Manufacturing Belgium NV in China, 2010-2014
Chart Sales Value and Market Share of Latanoprost Made by Pharmacia & Upjohn (Belgium) in China, 2010-2014
Chart Sales Value and Market Share of Latanoprost Made by Lunan Better Pharmaceutical Co., Ltd in China, 2010-2014
Chart Sales Value and Market Share of Latanoprost Made by Other Manufacturers in China, 2010-2014
Chart Price of Latanoprost Made by Pfizer Manufacturing Belgium NV in Some Chinese Cities in 2014
Chart Price of Latanoprost Made by Pharmacia & Upjohn (Belgium) in Some Chinese Cities in 2014
Chart Price of Latanoprost Made by Lunan Better Pharmaceutical Co., Ltd in Some Chinese Cities in 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *